Use of sodium–glucose cotransporter 2 inhibitors in Alberta adults with chronic kidney disease: a cross-sectional study identifying care gaps to inform knowledge …
Background: Sodium–glucose cotransporter 2 (SGLT2) inhibitors have important kidney and
cardiovascular benefits in adults with chronic kidney disease. Among adults with diabetes …
cardiovascular benefits in adults with chronic kidney disease. Among adults with diabetes …
Prescribing patterns of sodium-glucose cotransporter-2 inhibitors in patients with CKD: a cross-sectional registry analysis
M Zhuo, J Li, LF Buckley, SL Tummalapalli… - Kidney360, 2022 - journals.lww.com
Background Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduce kidney disease
progression and mortality in patients with chronic kidney disease (CKD), regardless of …
progression and mortality in patients with chronic kidney disease (CKD), regardless of …
Patient and provider characteristics associated with sodium–glucose cotransporter 2 inhibitor prescription in patients with diabetes and proteinuric chronic kidney …
Despite accumulating evidence of cardiorenal benefits from sodium–glucose cotransporter 2
(SGLT2) inhibitors, prescription of agents in this drug class may be limited by concerns …
(SGLT2) inhibitors, prescription of agents in this drug class may be limited by concerns …
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
Background Cardiovascular and kidney outcome trials have shown that sodium-glucose co-
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …
transporter-2 (SGLT2) inhibitors slow progression of chronic kidney disease in patients with …
Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan chronic kidney disease database
H Nagasu, Y Yano, H Kanegae, HJL Heerspink… - Diabetes …, 2021 - Am Diabetes Assoc
OBJECTIVE Randomized controlled trials have shown kidney-protective effects of sodium–
glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested …
glucose cotransporter 2 (SGLT2) inhibitors, and clinical practice databases have suggested …
Safety of sodium-glucose cotransporter-2 inhibitors in patients with CKD and type 2 diabetes: population-based US cohort study
EL Fu, E D'Andrea, DJ Wexler, E Patorno… - Clinical Journal of the …, 2023 - journals.lww.com
Background Limited information exists regarding the safety of sodium-glucose cotransporter-
2 inhibitors (SGLT2i) in patients with CKD treated in routine care. We evaluated the safety of …
2 inhibitors (SGLT2i) in patients with CKD treated in routine care. We evaluated the safety of …
Sodium‐glucose cotransporter‐2 inhibitors and kidney outcomes in real‐world type 2 diabetes populations: A systematic review and meta‐analysis of observational …
AK Forbes, RJ Suckling, W Hinton… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To conduct a systematic review of observational studies to explore the real‐world
kidney benefits of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in a large and diverse …
kidney benefits of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors in a large and diverse …
Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: impact of the 2020 KDIGO clinical practice guidelines
Background Sodium glucose transporter 2 inhibitors (SGLT2-i) reduce renal and
cardiovascular events in patients with type 2 diabetes (T2D) and their use is recommended …
cardiovascular events in patients with type 2 diabetes (T2D) and their use is recommended …
Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
SJ Jeong, SE Lee, DH Shin, IB Park, HS Lee, KA Kim - BMC nephrology, 2021 - Springer
Background Sodium-glucose cotransporter 2 inhibitor (SGLT2i) should be considered for
patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) having estimated …
patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) having estimated …
Predictors, disparities, and facility-level variation: SGLT2 inhibitor prescription among US veterans with CKD
LP Gregg, DJ Ramsey, JM Akeroyd, SA Jafry… - American Journal of …, 2023 - Elsevier
Rationale & Objective Sodium/glucose cotransporter 2 (SGLT2) inhibitors are recommended
for type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease (CKD) or …
for type 2 diabetes mellitus (T2DM) in patients with chronic kidney disease (CKD) or …
Related searches
- glucose cotransporter kidney disease
- alberta adults kidney disease
- glucose cotransporter alberta adults
- glucose cotransporter use of sodium
- use of sodium kidney disease
- knowledge translation kidney disease
- knowledge translation alberta adults
- glucose cotransporter knowledge translation
- use of sodium alberta adults
- knowledge translation use of sodium
- sglt2 inhibitors cotransporter 2
- sglt2 inhibitors kidney disease
- sglt2 inhibitors sodium glucose
- patients with diabetes kidney disease
- sodium glucose patients with ckd
- sodium glucose kidney outcomes
